miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases

Cisplatin is a first-line chemotherapy drug that is commonly used in the treatment of epithelial ovarian cancer (EOC). However, insensitivity to cisplatin markedly influences the outcomes of chemotherapy. MicroRNAs (miRNAs/miRs) have been demonstrated to modulate drug resistance in a number of types...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jue, Zhang, Xiaobo, Huang, Yuliang, Zhang, Qunfeng, Zhou, Jianbin, Zhang, Xiaodi, Wang, Xiaoxu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341622/
https://www.ncbi.nlm.nih.gov/pubmed/30675199
http://dx.doi.org/10.3892/ol.2018.9745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341622/
https://www.ncbi.nlm.nih.gov/pubmed/30675199
http://dx.doi.org/10.3892/ol.2018.9745

Ejemplares similares